Background-Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart failure with preserved ejection fraction. Methods and Results-We examined the prevalence of elevated high-sensitivity troponin T (hs-TnT) in 298 patients with heart failure with preserved ejection fraction enrolled in the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced markers of heart failure severity compared with valsartan. We assessed the association between hs-TnT and cardiac structure and function, and the effect of LCZ696, compared with valsartan, on hs-TnT over 36 weeks. Elevated hs-TnT in the myocardial injury range (>0.014 μg/L) was found in 55% of patients and was associated with older age, history of diabetes mellitus, higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular filtration rate, and larger left atrial size, left ventricular volume, and mass. LCZ696 treatment reduced hs-TnT to a greater extent at 12 weeks (12% reduction; P=0.05) and at 36 weeks (14% reduction; P=0.03) compared with valsartan. Conclusions-Troponin T was elevated in a substantial number of patients enrolled in a heart failure with preserved ejection fraction clinical trial and was associated with abnormalities of cardiac structure, function, and elevated baseline N-terminal pro-brain natriuretic peptide. Decreases in hs-TnT with LCZ696 in parallel with improvement in N-terminal pro-brain natriuretic peptide and left atrial size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may reduce this measure of myocardial injury in heart failure with preserved ejection fraction. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00887588.
M
yocardial damage is one of the central pathophysiological processes in heart failure with reduced ejection fraction (HFrEF). Ongoing myocardial damage detected with standard and high-sensitivity troponin assays [1] [2] [3] [4] has been demonstrated during acute decompensation and in stable outpatients with HF. 3 Higher detectable troponin concentrations have been associated with abnormalities of cardiac structure and function 5, 6 and poorer prognosis in HFrEF. 7 Heart November 2014 failure with preserved ejection fraction (HFpEF) accounts for up to 50% of cases of heart failure. While elevated troponin has been detected in hospitalized patients with HFpEF, [8] [9] [10] whether troponin is detectable in stable outpatients with HFpEF, and whether elevations in troponin are related to abnormalities of cardiac structure and function, is unknown. [10] [11] [12] [13] The Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial was a phase II trial testing the safety and efficacy of LCZ696 in stable outpatients with HFpEF. PARAMOUNT demonstrated that LCZ696 reduced N-terminal pro-brain natriuretic peptide (NT-proBNP) at 12 weeks and left atrial size and New York Heart Association (NYHA) class at 36 weeks. 14 We examined the prevalence and correlates of biochemical evidence of myocardial damage, detected using high-sensitivity troponin-T (hs-TnT), and whether therapy with LCZ696 affected hs-TnT in patients with HFpEF.
Methods
The design and results of the PARAMOUNT trial (registered at ClinicalTrials.gov, NCT00887588) have been previously published. 14 PARAMOUNT was a randomized, double-blind, parallel-group, active-controlled trial. Men and women aged ≥40 years with a left ventricular ejection fraction ≥45% and with a documented history of heart failure with associated signs or symptoms were eligible for randomization. Patients were required to have a NT-proBNP level of ≥400 pg/mL at screening, be on diuretic therapy, and have a systolic blood pressure ≤140 mm Hg, or ≤160 mm Hg if on 3 or more blood pressure drugs at randomization, have an estimated glomerular filtration rate (eGFR) ≥30 mL/min per 1.73 m 2 at screening, and a potassium concentration ≤5.2 mmol/L. Treatment assignment was stratified by previous use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and region. The primary end point was change in NT-proBNP from baseline to 12 weeks. The study protocol was approved by all individual site institutional review boards and ethics committees, and all recruited patients gave written informed consent.
NT-proBNP was measured at screening, randomization, week 4, week 12, and week 36 or at an earlier end of study visit if premature termination. NT-proBNP was measured at a central laboratory (Quest Diagnostics, Valencia, CA) with the Elecsys NT-proBNP immunoassay (Roche Diagnostics, Indianapolis, IN). Samples were taken for hs-TnT at randomization, 12 weeks and 36 weeks. Plasma hs-TnT was measured using the high-sensitivity Roche Elecsys assay (lot number 167345; Roche Diagnostics GmbH, Mannheim, Germany) at a central laboratory (Clinical Reference Laboratory-Europe Ltd, UK). The between-run variation of hs-TnT levels below the limit of quantification (0.013 μg/L) was not sufficiently high to permit analysis of the actual values. However, as a sensitivity analysis, we imputed a value of half the lower limit of quantification, as has been performed previously with this assay, 15 and imputed a value near to the limit of quantification (0.012 μg/L) to limit any bias from imputing a value too far from the lowest measured value. All samples were stored at -80°C and analyzed in a batch. There was no difference between treatment groups in the duration of storage (P=0.70). A hs-TnT sample was available for 298 patients. Echocardiography was performed at screening, randomization, week 12, and week 36 or at end of study or early termination visits. Analyses were conducted at a core laboratory (Brigham and Women's Hospital, Boston, MA). Measurements were made in triplicate in accordance with the recommendations of the American Society of Echocardiography. 16 Myocardial strain was analyzed, as previously described.
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Statistical Analysis
For patients with a hs-TnT value below the lower limit of quantification (<0.013 μg/L), we imputed half the lower limit of quantification. 15 Correlation between hs-TnT and logNT-proBNP was assessed using the Spearman correlation. Associations between categories of hs-TnT and baseline variables were examined using t tests and χ 2 tests where appropriate, with the exception of NT-proBNP, which was tested using the Wilcoxon rank-sum test due to skewness, and NYHA class, which used the Fisher exact test. Associations between baseline variables and categories of change in hs-TnT from baseline to 36 weeks (decrease, no change, or increase) were conducted via trend test across change categories. NT-proBNP was assessed using the Cuzick nonparametric trend test. The end point of change in hsTnT was analyzed using multiple linear regression with postbaseline log-transformed hs-TnT as the outcome, randomized treatment and the stratification variables (previous use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and region) as fixed factors, and the baseline log-transformed hs-TnT as a covariate. ; therefore, the values were log transformed. We examined the end point of change in hs-TnT using a binary outcome of hs-TnT>0.014 μg/L and hs-TnT ≤0.014 μg/L, ie, within or above the 99th centile of the general population and the cutoff used to define myocardial injury, using logistic regression adjusting for the variables above. As sensitivity analyses, we used linear regression models in which an alternate value (0.012) was imputed for those below the lower limit of quantification , and finally we performed an analysis of change in hs-TnT that was insensitive to the value of hs-TnT imputed for the lower limit of quantification , ordinal logistic regression adjusted for baseline log hs-TnT. We also performed analyses incorporating both 12-and 36-week observations as repeated measures, using random intercept linear regression models and ordinal and binary logistic regression models with standard errors adjusted for clustered data. We examined interactions between treatment and week of hs-TnT measurement (12 weeks and 36 weeks). Finally in a multivariable model (adjusting for age, sex, NYHA class, NT-proBNP, heart rate, body mass index, systolic blood pressure, eGFR, prior history or heart failure hospitalization, atrial fibrillation, myocardial infarction, ejection fraction, E/E′, left atrial volume index, left ventricular end-diastolic diameter), we assessed the predictors of baseline log hs-TnT and change in log hs-TnT at 12 and 36 weeks. All analyses were performed using STATA version 12 (StataCorp, College Station, TX). A P value of <0.05 was considered significant.
Results
At baseline, the majority of patients (164, 55%) had a hs-TnT level in the range consistent with myocardial injury (>0.014 μg/L; Figure 1 ). Patients with an elevated hs-TnT were older, more likely to have a history of diabetes mellitus , had lower diastolic blood pressure, and were less likely to be taking a β-blocker (Table1). In addition, those with higher hs-TnT had higher NTproBNP (r=0.43; P<0.001) and lower eGFR (r=-0.35; P<0.001).
We noted several differences in cardiac structure in patients with an elevated troponin ( Table 2) , including larger left atrial diameter, left ventricular volume, and greater left ventricular mass. We observed no differences in measures of cardiac systolic or diastolic function, including left ventricular ejection fraction, global longitudinal strain, E′, or E/E′ ratios among patients with and without elevated hs-TnT. Tricuspid regurgitant velocity was higher in the group with an elevated hs-TnT.
Over the course of 36 weeks, hs-TnT fell in both the LCZ696 and the valsartan groups ( Figure 2 ), with the majority of patients still having a hs-TnT in the myocardial injury range (Figure 1 ). The characteristics of those whose hs-TnT level fell, remained unchanged, or increased are given in Table 3 . Change in hs-TnT correlated with change in NT-proBNP at 36 weeks (r=0.35; P<0.001),but not at 12 weeks (r=0.12; P=0.06). We found no correlation between changes in systolic blood pressure and hs-TnT at 12 weeks (r=-0.09; P=0.15) and weak correlation between change in systolic blood pressure and hs-TnT at 36 weeks (r=-0.15; P=0.03). There was no association between change in hs-TnT at 12 or 36 weeks and change in E′ (P=0. 16 and P=0.81, respectively) or change in E/E′ (P=0.11 and P=0.34, respectively). In a multivariable model, female sex (P=0.004), prior MI (P=0.016), and higher eGFR (P<0.001) were associated with lower hs-TnT at baseline, whereas higher NT-proBNP was associated with higher hs-TnT at baseline (P<0.001). At 12 weeks, except for baseline hs-TnT, no variables were associated with change in hs-TnT. At 36 weeks in addition to baseline hs-TnT, NT-proBNP was associated with change in log hs-TnT (coefficient -0.14 per 1 log unit increase; P=0.002) as was age (coefficient 0.02 per 1 year increase; P<0.001), systolic blood pressure (coefficient -0.01 per 1 mm Hg change; P=0.008), eGFR (coefficient -0.01 per 1 mL/min/m 2 increase; P<0.001), and E/E′ (coefficient 0.02 per 1 unit increase; P=0.02).
Compared with valsartan, treatment with LCZ696 was associated with greater reduction in hs-TnT (Tables 4 and 5 ; Values are mean with SD and n (%) unless specified. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association. Downloaded from http://ahajournals.org by on February 13, 2020 Figure 2 ). The ratio of change in hs-TnT with LCZ696 in comparison with valsartan was 0.88 (95% confidence interval, 0.77-1.00, P=0.05) at 12 weeks and 0.86 (95% confidence interval, 0.75-0.99, P=0.03) at 36 weeks using an imputed value of half the lower limit of quantification in those with a hs-TnT below this limit. We observed a similar degree of reduction in hs-TnT by analyzing hs-TnT as a binary variable in a logistic regression model, as an ordinal variable in an ordinal logistic regression model, and after imputing a value for those under the limit of quantification that was closer to the limit of quantification of hs-TnT (Table 5) . When repeated measures models were used, a consistent treatment effect of LCZ696 on hs-TnT levels was observed (Tables 4 and 5) , with no significant interactions between treatment effect and follow-up time.
Discussion
In a well-characterized cohort of patients with HFPEF, we found that the majority of patients had a hs-TnT concentration above the threshold for diagnosis of myocardial injury. Higher hs-TnT concentrations were associated with several features that are known to be related to worse outcome in HFpEF, including increasing age, higher NT-proBNP, and lower eGFR, and were associated with abnormalities of cardiac structure. Treatment with the angiotensin receptor neprilysin inhibitor LCZ696 resulted in greater reduction in hs-TnT levels for 36 weeks in comparison with treatment with valsartan, suggesting that LCZ696 may reduce this measure of myocardial injury in HFpEF via potentiation of natriuretic peptides 17 (see below). Although elevated troponin is now well described in HFrEF, 3 prior studies on the relationship between troponin and HFpEF have concentrated on patients who are hospitalized or acutely decompensated. [8] [9] [10] Our population was similar to other trials of patients with HFpEF 18 but generally younger with fewer comorbidities than community-based cohorts of patients with HFpEF. 19 We found that 58% had a hs-TnT level in the myocardial injury range, a result similar to that observed in HFrEF. In the Controlled Rosuvastatin Multinational Trial in HF (CORONA), 49% of patients had a hs-TnT level above the limit for the detection of myocardial injury (0.014 μg/L) using a Roche assay. 6 In the Valsartan Heart Failure Trial (Val-HeFT) 7 and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure trial (GISSI-HF), 47% and 64% of patients had a hs-TnT level above the limit of detection for myocardial injury (0.0135 μg/L) using a Roche hs-TnT assay. 7 By comparison, in a population-based study of men and women aged 54 to 74 years, 7.4% of individuals had a hs-TnT in the myocardial injury range (>0.014 μg/L).
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Unlike ADHF where troponin elevation may be related to an acute precipitant, and acute decompensation can lead to volume overload and increased ventricular wall stress, the finding of elevated troponin in stable HFpEF is suggestive of ongoing subclinical myocardial injury. Few patients had an acute precipitant to explain the troponin elevations. In the patients without a serious adverse event during the trial, 54% had a hs-TnT level in the injury range at baseline, 49% at 12 weeks, and 47% at 36 weeks. Furthermore, only 24% of patients with a hs-TnT in the injury range at 36 weeks had experienced a serious adverse event at any point in the study. However, ongoing myocardial injury may be part of the process that explains the high morbidity and mortality in HFpEF. 21 The finding of increased left ventricular size and mass, increased left atrial size, and elevated NT-proBNP in patients with elevated troponin suggests that increased wall stress may be a potential mechanism for the observed elevation. Stretching of myocytes can lead to the release of angiotensin II, increased oxidative stress, architectural rearrangement, and eventual cell death. 22, 23 Moreover, troponin can be released from viable myocytes when stretched or subjected to ischemia. 24 Higher hs-TnT was also associated with higher myocardial mass and ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; hs-TnT, highsensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association. tricuspid regurgitant velocity. The relative contribution of myocardial hypertrophy and fibrosis, 25 the right heart, 23,26 and the microcirculation and repetitive ischemia 27 to the troponin concentrations observed remains to be determined.
We found that 36 weeks of therapy with LCZ696 compared with valsartan resulted in a modest reduction in troponin. These findings are consistent with the previously reported findings from the PARAMOUNT trial, 14 including reduction of NT-proBNP at 12 weeks, and reduction in left atrial size and improvement in NYHA class at 36 weeks. This suggests that neprilysin inhibition by LCZ696 and potentiation of natriuretic peptides leading to a reduction in wall stress may reduce troponin leakage in parallel with reduction in NT-proBNP and left atrial size. Although change in hs-TnT correlated with change in systolic blood pressure, the effect of treatment on hs-TnT was independent of the changes in blood pressure in keeping with our prior observations on the action of the drug on NT-proBNP and echocardiographic parameters. 28 Whether elevated troponin levels are associated with poorer prognosis in HFpEF is unknown, although this is likely given the associations that have been observed in HFrEF 7 and possibly HFpEF in the acute decompensated setting. 9 Moreover, whether a therapy that reduces hs-TnT levels would reduce morbidity and mortality in this population is unclear.
Some limitations of this analysis should be noted. PARAMOUNT was a relatively short-term study, and we thus cannot determine whether elevations in troponin are related to prognosis. Our data provide no direct insight into the mechanisms of troponin release in HFpEF, although the relationship among troponin, cardiac structure, and NT-proBNP suggest that elevated wall stress may be a common mechanism to account for elevation in both biomarkers. With limited information on right-sided hemodynamic indices, we cannot assess the contribution of the pulmonary vasculature and right side of the heart to the raised troponin levels we observed. 26 Our cohort may represent patients with more severe HF as entry into the trial required an NT-proBNP level of >400 pg/mL. Therefore, our results may not be applicable to patients with HFpEF and low NT-proBNP levels. The ejection fraction in this trial was >50% in 86% of patients. We could not specifically examine those patients with an ejection fraction at the lower end of the ejection fraction spectrum (45% to 50%).
In summary, we observed elevation in hs-TnT in a well-characterized HFpEF population, which was associated with larger left ventricular and atrial size, as well as higher NT-proBNP. These findings suggest that ongoing myocardial chronic troponin release, either because of myocyte stretch or injury, may contribute to the pathophysiology of HFpEF. LCZ696 reduced hs-TnT modestly compared with valsartan. Whether chronic reduction in hs-TnT can be achieved and whether this would lead to improved outcomes in HFpEF remains to be tested.
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